- Home
- YHNA vs DERM Comparison
YHNA vs DERM Comparison
Compare YHNA & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YHNA
- DERM
- Stock Information
- Founded
- YHNA 2023
- DERM 2014
- Country
- YHNA Hong Kong
- DERM United States
- Employees
- YHNA N/A
- DERM N/A
- Industry
- YHNA
- DERM Biotechnology: Pharmaceutical Preparations
- Sector
- YHNA
- DERM Health Care
- Exchange
- YHNA Nasdaq
- DERM Nasdaq
- Market Cap
- YHNA 79.9M
- DERM 87.4M
- IPO Year
- YHNA 2024
- DERM 2021
- Fundamental
- Price
- YHNA $10.07
- DERM $3.66
- Analyst Decision
- YHNA
- DERM Strong Buy
- Analyst Count
- YHNA 0
- DERM 3
- Target Price
- YHNA N/A
- DERM $9.50
- AVG Volume (30 Days)
- YHNA 21.1K
- DERM 63.2K
- Earning Date
- YHNA 01-01-0001
- DERM 11-12-2024
- Dividend Yield
- YHNA N/A
- DERM N/A
- EPS Growth
- YHNA N/A
- DERM N/A
- EPS
- YHNA N/A
- DERM N/A
- Revenue
- YHNA N/A
- DERM $57,771,000.00
- Revenue This Year
- YHNA N/A
- DERM N/A
- Revenue Next Year
- YHNA N/A
- DERM $36.49
- P/E Ratio
- YHNA N/A
- DERM N/A
- Revenue Growth
- YHNA N/A
- DERM N/A
- 52 Week Low
- YHNA $10.00
- DERM $2.85
- 52 Week High
- YHNA $11.28
- DERM $6.89
- Technical
- Relative Strength Index (RSI)
- YHNA N/A
- DERM 29.46
- Support Level
- YHNA N/A
- DERM $3.54
- Resistance Level
- YHNA N/A
- DERM $4.00
- Average True Range (ATR)
- YHNA 0.00
- DERM 0.36
- MACD
- YHNA 0.00
- DERM -0.01
- Stochastic Oscillator
- YHNA 0.00
- DERM 12.77
About YHNA YHN Acquisition I Limited Ordinary Shares
YHN Acquisition I Ltd is a newly organized blank check company for the purpose of acquiring, engaging in a share exchange, share reconstruction and amalgamation, purchasing all or substantially all of the assets of, entering into contractual arrangements, or engaging in any other similar business combination with one or more businesses or entities.
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's portfolio includes eight branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.